



1635
IFW

Practitioner's Docket No. MPI00-459P1RM (formerly 10147-56U1)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Meyers, Rachel E., *et al.*
Application No.: 10/001,851 Group No.: 1635
Filed: November 20, 2001 Examiner: Schultz, James
For: 47169 AND 33935, NOVEL HUMAN GLYCOSYL TRANSFERASES AND USES
THEREFOR

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (2 pages- in duplicate);
 - b. Amendment and Response to Notice of Non-Responsive Amendment (14 pages);
 - c. Transmittal of Information Disclosure Statement (2 pages-in duplicate);
 - d. Information Disclosure Statement (2 pages);
 - e. Forms PTO/SB/08A (1 page) and PTO/SB/08B (4 pages) (substitute for Form PTO-1449);
 - f. Copy of Listed Information Items Accompanying This Statement (Cite Nos. AB, CA-CZ);
 - g. Statement of Limited Recognition under 37CFR §10.9(b) for Mario Cloutier (1 page); and
 - h. Return Postcard.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature: 

Date: October 5, 2004

Sean Hunziker
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a n/a extension:

Fee: \$0.00

Extension fee due with this request \$0.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Addit. Fee
Total	29	Minus	35	=	0	\$18.00 =	\$0.00
Indep.	4	Minus	4	=	0	\$88.00 =	\$0.00
First Presentation of Multiple Dependent Claims			yes			\$300.00 =	\$0.00
						Total Addit. Fee	\$0.00

Total additional fee for claims required \$0.00

FEE PAYMENT


5. Charge Account No. 501668 the sum of \$0.00 (which includes the \$0.00 extension fee). A duplicate of this transmittal is attached.

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

October 5, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By 
Mario Cloutier
Limited Recognition Under 37 C.F.R. §10.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820